Sulfonylureas are associated with a higher likelihood of serious hypoglycaemia than metformin, meglitinides or thiazolidinediones, according to the first study to “examine and compare” the risk in patients treated with monotherapy in a real-world setting.

The authors defined serious hypoglycaemia as needing hospitalisation or treatment in an emergency department. Based on this definition, the incidence of serious hypoglycaemia varied from 68.0 per 1,000 patient years’ follow-up for glyburide to 11.9 per 1,000 patient years for metformin.

After allowing for confounders, the risk of serious hypoglycaemia was highest with glyburide (hazard ratio [HR] 3.95 versus metformin), glimepiride (HR 3.28) and glipizide (HR 2.57). The increased risk compared to metformin was less marked with repaglinide (HR 2.03), nateglinide (HR 1.21), rosiglitazone (HR 0.90) and pioglitazone (HR 0.80).

The risk of serious hypoglycaemia increased with higher average daily doses. For example, the incidence rose from 8.8 to 13.4 per 1,000 patient years with low and high doses of metformin respectively. The incidence was 37.2 and 66.8 with repaglinide and 64.5 and 74.3 with glyburide.

Sulfonylureas and meglitinides produce a dose-dependent stimulation of insulin secretion. In addition, patients receiving higher doses usually have serious diabetes and are more likely to show fluctuating glycaemic control – factors which may account for the dose-response relationship.

Pharmacoepidemiol Drug Saf DOI:10.1002/pds.4337

Recommended

Pharmacists help prevent AF-related strokes

A pharmacist-led programme has helped to reduce the number of stokes related to atrial fibrillation by a third

Clinical briefing: Aspirin and cancer

A growing body of evidence is suggesting that aspirin reduces the risk of certain cancers




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.